BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glioma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Glioma\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06258018-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06258018)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Niraparib and 
 Temozolomide in Patients Glioblastoma\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 258018
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643549-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03643549)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Bortezomib and
  Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORT
 EM-17)\nEstimated primary completion: 30 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03643549
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06703255-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06703255)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: A Phase 2 Study of H
 X301 in Patients with High-grade Giloma\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozo
 lomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06703255
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623931-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04623931)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Chemotherapy and
  Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histol
 ogical (Molecular) Glioblastomas\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0462
 3931
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00978458-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT00978458)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Radiation Therapy With
  or Without Temozolomide in Treating Patients With Low-Grade Glioma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT00978458
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330337-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT06330337)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Effect of Electroacupu
 ncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurre
 nce of High-grade Glioma\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06330337
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05188508-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05188508)
DESCRIPTION:Temozolomide\, phase 2\, Glioma.\nStudy: Pembrolizumab\, Olapar
 ib\, and Temozolomide for People With Glioma\nEstimated primary completion
 : January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05188508
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413706-2159@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06413706)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Glioma.\nStudy: A Study Comp
 aring Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Childre
 n and Young Adults With High-grade Glioma Following Radiotherapy\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06413706
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01837862-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT01837862)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase I Stud
 y of Mebendazole for the Treatment of Pediatric Gliomas\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT01837862
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03363217-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Trametinib: Phase 2 readout est. (NCT03363217)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Trametinib for Pediatric
  Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/
 ERK Pathway.\nEstimated primary completion: 1 March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03363217
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810544-2159@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06810544)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, Glioma.\nStudy: Safety and
  Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patie
 nts With Solid Tumors With MTAP Loss\nEstimated primary completion: 31 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0681
 0544
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271240-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Temozolomide: Phase 3 readout est. (NCT05271240)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Repeated Superse
 lective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozo
 lomide and Radiation Compared to Temozolomide and Radiation Alone in Newly
  Diagnosed GBM\nEstimated primary completion: 1 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05271240
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004075-7648@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Luvometinib: Phase 3 readout est. (NCT07004075)
DESCRIPTION:Luvometinib\, phase 3\, Glioma.\nStudy: FCN-159 Monotherapy Ver
 sus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Pa
 tients With BRAF Alteration\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07004075
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775485-2192@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT04775485)
DESCRIPTION:Tovorafenib\, phase 2\, Glioma.\nStudy: A Study to Evaluate Tov
 orafenib in Pediatric and Young Adult Participants With Relapsed or Progre
 ssive Low-Grade Glioma and Advance Solid Tumors\nEstimated primary complet
 ion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tov
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04775485
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05566795-2192@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tovorafenib: Phase 3 readout est. (NCT05566795)
DESCRIPTION:Tovorafenib\, phase 3\, Glioma.\nStudy: DAY101 vs. Standard of 
 Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requirin
 g First-Line Systemic Therapy (LOGGIC/FIREFLY-2)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tovo
 rafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05566795
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03919071-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trametinib: Phase 2 readout est. (NCT03919071)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Dabrafenib Combined With
  Trametinib After Radiation Therapy in Treating Patients With Newly-Diagno
 sed High-Grade Glioma\nEstimated primary completion: 30 September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03919071
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03919071-2236@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT03919071)
DESCRIPTION:Dabrafenib\, phase 2\, Glioma.\nStudy: Dabrafenib Combined With
  Trametinib After Radiation Therapy in Treating Patients With Newly-Diagno
 sed High-Grade Glioma\nEstimated primary completion: 30 September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03919071
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599371-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07599371)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: A Prospective\, Sing
 le-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With
  Temozolomide in the Treatment of Relapsed/Refractory Glioma\nEstimated pr
 imary completion: 10 October 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07599371
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06478212-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06478212)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Vorasidenib in Combi
 nation With Temozolomide (TMZ) in IDH-mutant Glioma\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06478212
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2236@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009992-3224@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dordaviprone: Phase 2 readout est. (NCT05009992)
DESCRIPTION:Dordaviprone\, phase 2\, Glioma.\nStudy: Combination Therapy fo
 r the Treatment of Diffuse Midline Gliomas\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dor
 daviprone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05009992
URL:https://assetmemo.bio/drug/dordaviprone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707973-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07707973)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Nimotuzumab Comb
 ined With the Stupp Regimen for Postoperative Residual Glioblastoma\nEstim
 ated primary completion: 3 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07707973
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504381-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06504381)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: DB107-RRV\, DB
 107-FC\, and Radiation Therapy With or Without Temozolomide (TMZ) for High
  Grade Glioma\nEstimated primary completion: 31 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06504381
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04945148-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04945148)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Oxidative Phosph
 orylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy 
 Temozolomide\nEstimated primary completion: May 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04945148
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03213002-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03213002)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Oral Capecitab
 ine and Temozolomide (CAPTEM) for Newly Diagnosed GBM\nEstimated primary c
 ompletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03213002
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05580562-3224@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dordaviprone: Phase 3 readout est. (NCT05580562)
DESCRIPTION:Dordaviprone\, phase 3\, Glioma.\nStudy: ONC201 in H3 K27M-muta
 nt Diffuse Glioma Following Radiotherapy (the ACTION Study)\nEstimated pri
 mary completion: June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dordaviprone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05580562
URL:https://assetmemo.bio/drug/dordaviprone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096481-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05096481)
DESCRIPTION:Temozolomide\, phase 2\, Glioma.\nStudy: PEP-CMV Vaccine Target
 ing CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurr
 ent Medulloblastoma\nEstimated primary completion: 15 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05096481
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02494804-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT02494804)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Effect of Cytokine-i
 nduced Killer Cells for Stage I-II Malignant Gliomas\nEstimated primary co
 mpletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02494804
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439172-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07439172)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Pre-Radiation Ch
 emotherapy for Newly Diagnosed High-Grade Glioma.\nEstimated primary compl
 etion: September 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07439172
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05476939-3224@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Dordaviprone: Phase 3 readout est. (NCT05476939)
DESCRIPTION:Dordaviprone\, phase 3\, Glioma.\nStudy: Biological Medicine fo
 r Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0\nEstimated prima
 ry completion: September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/dordaviprone#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05476939
URL:https://assetmemo.bio/drug/dordaviprone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326566-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07326566)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Study of Silever
 tinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unme
 thylated MGMT and EGFRvIII\nEstimated primary completion: November 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07326566
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712875-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT06712875)
DESCRIPTION:Trametinib\, phase 1/2\, Glioma.\nStudy: MAPK Inhibition Combin
 ed With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trametinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06712875
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712875-2236@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT06712875)
DESCRIPTION:Dabrafenib\, phase 1/2\, Glioma.\nStudy: MAPK Inhibition Combin
 ed With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06712875
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303519-10904@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:safusidenib: Phase 3 readout est. (NCT05303519)
DESCRIPTION:safusidenib\, phase 3\, Glioma.\nStudy: SIGMA (Safusidenib in I
 DH1 Mutant Glioma Maintenance)\nEstimated primary completion: 1 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/safusidenib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05303519
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391215-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07391215)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: 5G-PEARL: Paxa
 lisib in Malignant Brain Tumours\nEstimated primary completion: 19 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07391
 215
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832123-10904@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:safusidenib: Phase 2 readout est. (NCT07832123)
DESCRIPTION:safusidenib\, phase 2\, Glioma.\nStudy: Safusidenib for Patient
 s With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and A
 strocytoma - a Single Arm Phase II Study\nEstimated primary completion: Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/safusidenib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 32123
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712757-10904@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:safusidenib: Phase 3 readout est. (NCT07712757)
DESCRIPTION:safusidenib\, phase 3\, Glioma.\nStudy: Safety and Efficacy Stu
 dy of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma\nEstimat
 ed primary completion: May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safusidenib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07712757
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161974-2857@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06161974)
DESCRIPTION:Olutasidenib\, phase 2\, Glioma.\nStudy: Study of Olutasidenib 
 and Temozolomide in HGG\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06161974
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754734-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07754734)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: STUPP Regimen Wi
 th or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promot
 er Methylation\nEstimated primary completion: 31 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07754734
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843253-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05843253)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Study of Ribocic
 lib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG\,
  H3G34-mutant\nEstimated primary completion: 31 August 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05843253
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630260-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06630260)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: 5G-RUBY: Avuto
 metinib and Defactinib in Malignant Brain Tumours\nEstimated primary compl
 etion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06630260
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243470-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07243470)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Combination of Tarla
 tamab and Temozolomide in Patients With Central Nervous System Tumors\nEst
 imated primary completion: October 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07243470
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440290-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Trametinib: Phase 2/3 readout est. (NCT07440290)
DESCRIPTION:Trametinib\, phase 2/3\, Glioma.\nStudy: DETERMINE Trial Treatm
 ent Arm 07: Dabrafenib in Combination With Trametinib in Adult\, Paediatri
 c and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancer
 s.\nEstimated primary completion: October 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07440290
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440290-2236@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Dabrafenib: Phase 2/3 readout est. (NCT07440290)
DESCRIPTION:Dabrafenib\, phase 2/3\, Glioma.\nStudy: DETERMINE Trial Treatm
 ent Arm 07: Dabrafenib in Combination With Trametinib in Adult\, Paediatri
 c and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancer
 s.\nEstimated primary completion: October 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07440290
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00887146-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT00887146)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Radiation Therapy With
  Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuv
 ant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Gliom
 a\nEstimated primary completion: 31 October 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT00887146
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206849-2192@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Tovorafenib: Phase 2 readout est. (NCT07206849)
DESCRIPTION:Tovorafenib\, phase 2\, Glioma.\nStudy: Study of Tovorafenib in
  High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)\nEstimated 
 primary completion: February 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tovorafenib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07206849
URL:https://assetmemo.bio/drug/tovorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859059-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07859059)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Metronomic Tem
 ozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblas
 toma\nEstimated primary completion: 1 June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07859059
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703436-10904@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:safusidenib: Phase 2 readout est. (NCT07703436)
DESCRIPTION:safusidenib\, phase 2\, Glioma.\nStudy: Safety and Efficacy Stu
 dy of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued
  Vorasidenib Treatment Due to Progressive Disease\nEstimated primary compl
 etion: September 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/safusidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07703436
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562971-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07562971)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Focused Ultrasound B
 lood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Te
 mozolomide Therapy: Pilot Feasibility Study (FIDES)\nEstimated primary com
 pletion: November 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07562971
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180825-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20311101
DTEND;VALUE=DATE:20311102
SUMMARY:Trametinib: Phase 2 readout est. (NCT05180825)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Pediatric Low Grade Glio
 ma - MEKinhibitor TRIal vs Chemotherapy\nEstimated primary completion: 1 N
 ovember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trameti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05180825
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110246-1979@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Trametinib: Phase 2 readout est. (NCT07110246)
DESCRIPTION:Trametinib\, phase 2\, Glioma.\nStudy: Dabrafenib and Trametini
 b for BRAF V600 Mutant Low-Grade Gliomas\nEstimated primary completion: 31
  March 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7110246
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110246-2236@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT07110246)
DESCRIPTION:Dabrafenib\, phase 2\, Glioma.\nStudy: Dabrafenib and Trametini
 b for BRAF V600 Mutant Low-Grade Gliomas\nEstimated primary completion: 31
  March 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafen
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7110246
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389278-8999@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07389278)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Combination AD
 I-PEG 20\, TMZ\, and RT for Treatment of Newly Diagnosed High-grade Glioma
  (HGG)\nEstimated primary completion: 30 June 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07389278
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
